stockrowKrystal Biotech, Inc.
KRYS Healthcare Biotechnology
Krystal Biotech, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $389.1 million, up 33.9% from fiscal 2024.
- Revenue
- +30.2%
- EPS
- −22.3%
- Free cash flow
- +137.8%
Quarter to September 2026, against a year earlier
Follow KRYS
Alert me
Krystal Biotech, Inc. (KRYS) Shares outstanding
Krystal Biotech, Inc.'s shares outstanding at the end of fiscal 2025 was $30.0M, unchanged from fiscal 2024. At the end of the quarter to 30 September 2026 it was $30.8M. Over the past ten years it has ranged from $877.5K (fiscal 2016) to $30.0M (fiscal 2025) — the current reading is the highest in ten years. Krystal Biotech, Inc. ranks 354th of 600 Biotechnology companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $30.0M | 0.71% |
| FY2024 | $29.7M | 7.16% |
| FY2023 | $27.8M | 8.87% |
| FY2022 | $25.5M | 14.84% |
| FY2021 | $22.2M | 18.15% |
| FY2020 | $18.8M | 18.15% |
| FY2019 | $15.9M | 41.94% |
| FY2018 | $11.2M | 108.97% |
| FY2017 | $5.4M | 510.94% |
| FY2016 | $877.5K | — |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Sep 2026 | $30.8M | 0.59% |
| Jun 2026 | $30.7M | 0.49% |
| Mar 2026 | $30.5M | 1.86% |
| Dec 2025 | $30.0M | 0.40% |
| 36 more quarters | Free account |
Against its own ten years
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| IBRX ImmunityBio, Inc. compare | $1.1B |
| CAI Caris Life Sciences,�Inc. compare | $295.1M |
| TGTX TG Therapeutics, Inc. compare | $157.3M |
| CYTK Cytokinetics, Incorporated compare | $132.1M |
| SYRE Spyre Therapeutics, Inc. compare | $88.4M |
| PTGX Protagonist Therapeutics, Inc. compare | $71.0M |
| TWST Twist Bioscience Corporation compare | $62.4M |
| KRYS Krystal Biotech, Inc. | $30.8M |
| MDGL Madrigal Pharmaceuticals, Inc. compare | $30.3M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on KRYS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Book value per share
- Altman Z-score
- The full statement